Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
The Source
TWSJ
Tech
Oracle Sheds 21,000 Jobs as It Continues AI-Focused Streamlining
TWSJ·1h ago·3 min read
Business
Tesla Notches Over Twofold Increase in European Monthly Sales
TWSJ·1h ago·3 min read
Business
Heineken Appoints JDE Peet’s Boss to Fill Vacant CEO Chair
TWSJ·1h ago·3 min read
Business
Gold Falls; Macro Challenges to Persist in Near Term
TWSJ·3h ago·3 min read
Related
On this beat
Health
7 Signs You Need Physical Therapy (And How To Find the Right Provider)
AOHL·2h ago·3 min read
Health
Doctors Thought It Was Asthma. A.I. Flagged a Serious Heart Problem.
TNYT·10h ago·3 min read
Health
More drug companies are taking their clinical trials to China and Australia. U.S. officials are making moves to keep them at home.
TWSJ·13h ago·3 min read
Health
The Hidden Hormone Controlling Your Energy, Mood, And Recovery
AOHL·15h ago·3 min read